NCT00535587 is a Phase 2 clinical trial of Exercise in Fibromyalgia, sponsored by Oregon Health and Science University.

Who is sponsoring NCT00535587?

NCT00535587 is sponsored by Oregon Health and Science University.

What drugs are being tested in NCT00535587?

Interventions in NCT00535587: Exercise, pyridostigmine, Placibo, Attention Control.

What condition does NCT00535587 study?

NCT00535587 studies Fibromyalgia.

Is NCT00535587 still recruiting?

NCT00535587 is currently completed. Last updated 23 March 2011.

Are results published for NCT00535587?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2011-03-23 · How we verify

NCT00535587

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maximizing Exercise Effectiveness in Fibromyalgia

Completed Phase 2 Results posted Last updated 23 March 2011

What this trial tests

Phase 2 trial testing Exercise in Fibromyalgia in 178 participants. Completed in 1 June 2008.

Timeline

1 September 2002

Primary endpoint
1 June 2008

1 June 2008

Quick facts

Lead sponsor	Oregon Health and Science University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	178
Start date	1 September 2002
Primary completion	1 June 2008
Estimated completion	1 June 2008
Sites	1 location across United States

Drugs / interventions tested

Exercise
pyridostigmine — full drug profile →
Placibo — full drug profile →
Attention Control

Conditions studied

Fibromyalgia — all drugs for Fibromyalgia →

Sponsor

Oregon Health and Science University

Who can join

Adults 21 to 65, any sex, with Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Levels of Growth Hormone Post Exercise
Time frame: 6 months
Serum growth hormone at peak V02/treadmill

Sponsor's own description

The purpose of this trial was to test the combined and independent effects of 6 months of exercise and Mestinon in people with fibromyalgia. Specifically, we wanted to determine if Mestinon helped people with fibromyalgia have an easier time exercising and if their symptoms improved by the end of the trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Exercise

Trials testing the same drug.

NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
NCT07007858 — Effects of High-Velocity Passive Stretch on Spasticity, Function, and Muscle Structure in Spastic CP Children · NA · enrolling by invitation
NCT07589725 — Mulligan Mobilization in Lateral Elbow Tendinopathy · NA · not yet recruiting
NCT07524400 — Effects of Physical Exercise Combined With Transcranial Direct Current Stimulation in Parkinson's Disease · NA · recruiting
NCT06627569 — Exercise Effects on the Neurobiology Underlying Stress-related Eating Behaviors in Veterans · NA · not yet recruiting

Other recruiting trials for Fibromyalgia

Currently open trials in the same condition.

NCT02285868 — ATI Evidence-based Guide Investigating Clinical Services · active not recruiting
NCT07245303 — Neural Mechanisms of Light Driven Analgesia · NA · recruiting
NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
NCT07358754 — The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor · recruiting
NCT07465991 — The Effect of Digital Cognitive Behavioural Therapy for Insomnia on Physical Activity in Fibromyalgia · NA · recruiting

Other Oregon Health and Science University trials

Trials by the same sponsor.

NCT07431970 — Assessing Construction Execution Under Sleep Impairment · NA · not yet recruiting
NCT07309757 — Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD) · not yet recruiting
NCT07282639 — App-Based Certified Diabetes Education Therapy (AB-CDE) · NA · not yet recruiting
NCT07322588 — Reentry Incentives and Support for Engagement With Contingency Management · NA · not yet recruiting
NCT07220590 — Implementing Powered Mobility in Early Childhood Settings for Children With Cerebral Palsy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00535587 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Oregon Health and Science University
Last refreshed: 23 March 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00535587.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing